Abbott Receives FDA Approval for TactiFlex Duo Ablation Catheter to Treat Atrial Fibrillation

Abbott has received U.S. Food and Drug Administration (FDA) approval for its TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, for the treatment of atrial fibrillation (AFib), including complex cases. This dual-energy catheter combines pulsed field ablation (PFA) and radiofrequency (RF) energy, allowing physicians to tailor treatment and create precise lesions while potentially sparing surrounding tissue. The approval is supported by positive safety and effectiveness data from Abbott's FlexPulse IDE study, which was also presented at the European Society of Cardiology (ESC) Congress 2026 and published in EP Europace.